Cargando…
Selective Serotonin Reuptake Inhibitors and Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation: An Analysis From the ROCKET AF Trial
BACKGROUND: There is concern that selective serotonin reuptake inhibitors (SSRIs) substantially increase bleeding risk in patients taking anticoagulants. METHODS AND RESULTS: We studied 737 patients taking SSRIs in the ROCKET AF (Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With...
Autores principales: | Quinn, Gene R., Hellkamp, Anne S., Hankey, Graeme J., Becker, Richard C., Berkowitz, Scott D., Breithardt, Günter, Fava, Maurizio, Fox, Keith A. A., Halperin, Jonathan L., Mahaffey, Kenneth W., Nessel, Christopher C., Patel, Manesh R., Piccini, Jonathan P., Singer, Daniel E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6201450/ https://www.ncbi.nlm.nih.gov/pubmed/30371223 http://dx.doi.org/10.1161/JAHA.118.008755 |
Ejemplares similares
-
Hospitalizations in patients with atrial fibrillation: an analysis from ROCKET AF
por: DeVore, Adam D., et al.
Publicado: (2016) -
Pharmacotherapy for diabetes and stroke risk: Results from ROCKET AF
por: Ugowe, Francis E., et al.
Publicado: (2021) -
Termination Based on Event Accrual in Per Protocol Versus Intention to Treat in the ROCKET AF Trial
por: Carnicelli, Anthony P., et al.
Publicado: (2021) -
Impact of Global Geographic Region on Time in Therapeutic Range on Warfarin Anticoagulant Therapy: Data From the ROCKET AF Clinical Trial
por: Singer, Daniel E., et al.
Publicado: (2013) -
Safety and Efficacy of Rivaroxaban in Patients With Cardiac Implantable Electronic Devices: Observations From the ROCKET AF Trial
por: Leef, George C., et al.
Publicado: (2017)